Paper Review Records
All Paper Review Records
29 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Chronic Lymphocytic Leukaemia as a Disease of Time: A Four‐Clock Framework for Therapeutic Stewardship
Fortunato Morabito; Enrica Antonia Martino; Ernesto Vigna; Massimo GentileShow moreShow less
1. Dafne Srl Reggio Calabria Italy; 2. Hematology Unit, Department of Onco‐Hematology AO of Cosenza Cosenza Italy; 3. Department of Pharmacy, Health and Nutritional Science University of Calabria Rende ItalyShow moreShow less
Efficacy, Safety, and Durability of Sutimlimab in Cold Agglutinin Disease: A Systematic Review and Meta‐Analysis
Jamiel Reyes; Alexander ReyesShow moreShow less
1. Department of Internal Medicine Universidad de Ciencias Médicas de Holguín Holguín Cuba; 2. Department of Software Engineering Universidad de Holguín Holguín CubaShow moreShow less
Comparative Prognostic Value of Mayo 2012 and European‐Modified Mayo 2004 Staging Systems in Systemic AL Amyloidosis With Discordant Risk Classification
Miran Han; Jun Ho Yi; Sang Eun Yoon; Seokjin Kim; Darae Kim; Jin‐Oh Choi; Jung Eun Lee; Jung‐Sun Kim; Ju‐Hong Min; Byoung Joon Kim; Kihyun KimShow moreShow less
1. Division of Hematology–Oncology, Department of Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul Korea; 2. Division of Hematology–Oncology, Department of Medicine Jeonbuk National University Medical School and Hospital Jeonju South Korea; 3. Division of Cardiology, Department of Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul Korea; 4. Division of Nephrology, Department of Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul Korea; 5. Department of Pathology and Translational Genomics Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul Korea; 6. Department of Neurology Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul KoreaShow moreShow less
Optimizing Frontline Targeted Therapies in Chronic Lymphocytic Leukemia: An Italian Inter‐Regional Delphi Consensus on Patient Risk Stratification, Cardiovascular Safety, and Endpoint Interpretation
Stefano Molica; Giacomo Loseto; Elsa Pennese; Francesco Aji; Angelo Fama; Annamaria Giordano; Giulio Giordano; Francesca Immacolata Merchionne; Rosanna Maria Miccolis; Gaetano Palumbo; Pamela Pinto; Sara Plebani; Stefania Scardino; Luana Schiattone; Antonio Giovanni Solimando; Maria Rosaria Specchia; Lorenzo Tonialini; Vincenzo Fraticelli; Potito Rosario Scalzulli; Daniela D'Angela; Stefano Oliva; Alessandro MaggiShow moreShow less
1. York‐Hull Medical School Hull UK; 2. UOC Ematologia, IRCCS Istituto Tumori “Giovanni Paolo II” Bari Italy; 3. UOC Ematologia Presidio Ospedaliero Pescara Pescara Italy; 4. UO Ematologia, Ospedale “Cardinale G. Panico” Tricase Italy; 5. UO Ematologia, Ospedale “Giuseppe Mazzini” Teramo Italy; 6. UO Ematologia, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari Bari Italy; 7. UO Ematologia, Ospedale “Antonio Cardarelli” Campobasso Italy; 8. UO Ematologia, Ospedale “A. Perrino” Brindisi Italy; 9. UO Ematologia, Ospedale “Mons. R. Dimiccoli” Barletta Italy; 10. UO Ematologia, Azienda Ospedaliero Universitaria Policlinico di Foggia Foggia Italy; 11. UO Ematologia, Ospedale “F. Miulli” Acquaviva delle Fonti Italy; 12. UO Ematologia, Presidio Ospedaliero “S. Salvatore” L'Aquila Italy; 13. UO Ematologia, Ospedale “Vito Fazzi” Lecce Italy; 14. UO Ematologia, Ospedale “Santo Spirito” Pescara Italy; 15. UO Medicina Interna, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari Bari Italy; 16. UO Ematologia, Ospedale “SS. Annunziata – Moscati” Taranto Italy; 17. UOC Ematologia, Policlinico “Gemelli” Molise Campobasso Italy; 18. UOC Ematologia, IRCCS “Casa Sollievo Della Sofferenza” San Giovanni Rotondo Italy; 19. Università Roma Tor Vergata Roma Italy; 20. UOSD Cardiologia, IRCCS Istituto Tumori “Giovanni Paolo II” Bari ItalyShow moreShow less
Patient‐Reported Symptom Burden and Objective Responses After Belumosudil in Heavily Pretreated Chronic GvHD
Sergio Rodriguez‐Rodriguez; Jennifer White; Kylie Lepic; Nihar Desai; Brittany Salter; Mohamed Elemary; Eshrak Al‐Shaibani; Tommy Alfaro‐Moya; Arjun D. Law; Igor Novitzky‐Basso; Ivan Pasic; Auro Viswabandya; Fotios V. Michelis; Rajat Kumar; Jonas Mattsson; Dennis D. H. KimShow moreShow less
1. University Health Network Princess Margaret Cancer Centre Toronto Ontario Canada; 2. University of Toronto Toronto Ontario Canada; 3. British Columbia Cancer Agency Vancouver General Hospital Vancouver British Columbia Canada; 4. University of British Columbia Vancouver British Columbia Canada; 5. Hamilton Health Sciences Juravinski Cancer Centre Hamilton Ontario Canada; 6. McMaster University Hamilton Ontario Canada; 7. Saskatchewan Cancer Agency Saskatoon Cancer Centre Saskatoon Saskatchewan Canada; 8. University of Saskatchewan Saskatoon Saskatchewan CanadaShow moreShow less
Efficacy and Safety of Doxorubicin–Etoposide–Methylprednisolone ( DEP )‐Based Regimens in Haemophagocytic Lymphohistiocytosis: A Systematic Review and Meta‐Analysis
Mostafa Rafea; Reem Hassan; Ahmed FayedShow moreShow less
1. London Northwest Healthcare NHS Trust Harrow UK; 2. London School of Hygiene and Tropical Medicine London UK; 3. Kasr Al‐Ainy School of Medicine, University of Cairo Cairo EgyptShow moreShow less
FAQ
How long does EUROPEAN JOURNAL OF HAEMATOLOGY take to review a manuscript?
As of 2026-11-17, CrushSCI has 29 complete review records for EUROPEAN JOURNAL OF HAEMATOLOGY. The fastest paper went from submission to acceptance in 1 days (Current Challenges in Pediatric Hematology and Oncology: An Integrated Multidisciplinary Perspective, received 2026-05-19, accepted 2026-05-20); the slowest took 331 days. The average is 58.7 days and the median is 48 days. The fastest record has an unusually short interval; please check the original source.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
